Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
NKTR
#1941
Nektar Therapeutics
73.250
0
USD
+4.11%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+4.11%
Changement Mensuel
-0.03%
Evolution sur 6 mois
-0.03%
Changement Annuel
-0.03%
Clôture Précédente
70.360
0
Open
73.250
0
Bid
73.250
0
Ask
73.253
0
Low
73.250
0
High
73.250
0
Volume
66
Marchés
Actions des Marchés US
Soins de Santé
NKTR
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
12.3 M
12.41 M
12.41 M
19.02 M
20.34 M
—
Valuation ratios
Enterprise value
—
—
—
448.45 M
1.12 B
—
Price to earnings ratio
—
—
—
-2.98
-7.25
—
Price to sales ratio
—
—
—
4.79
13.27
—
Price to cash flow ratio
—
—
—
1.95
4.49
—
Price to book ratio
—
—
—
2.43
4.9
—
Enterprise value to EBITDA ratio
—
—
—
—
-6.24
—
Profitability ratios
Return on assets %
0.12
-0.02
0.2
0.2
0.12
0.49
Return on equity %
0.76
-0.12
3.7
1.72
0.42
5.72
Return on invested capital %
233.59
-106.05
321.82
316.55
297.28
829.6
Gross margin %
81.62
72.66
100
100
100
372.66
Operating margin %
142.37
-49.18
425.76
324.21
268.63
969.43
EBITDA margin %
—
-109.97
-580.57
-406.73
-344.29
-1 441.57
Net margin %
153.61
-24.89
486.44
372.2
301.29
1 135.04
Liquidity ratios
Quick ratio
4.24
4.26
—
—
—
—
Current ratio
4.24
4.26
3.24
2.61
4.24
14.35
Inventory turnover
0.61
—
—
—
—
—
Asset turnover
0.07
0.1
0.04
0.05
0.05
0.23
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
3.15
3.37
3.49
3.25
2.57
12.68
EBIT per share
-2.53
-2.45
-4.41
-3.29
-2.22
-12.37
EBITDA per share
—
-2.34
-4.32
-3.23
-2.14
-12.03
Total debt per share
—
—
—
—
—
—
Cash per share
17.53
18.62
15.55
12.49
14.26
60.91
Net current asset value per share
20.54
19.06
16.35
13.24
14.85
63.5
Tangible book value per share
3.5
4.43
0.98
1.72
4.49
11.62
Working capital per share
15.69
14.58
11.31
8.18
11.35
45.41
Book value per share
3.5
4.43
0.98
1.72
4.49
11.62
Nouvelles
Oppenheimer relève l’objectif de cours de Nektar Therapeutics à 140$
Oppenheimer raises Nektar Therapeutics price target to $140
L’action Nektar Therapeutics atteint un sommet de 52 semaines à 76,3 dollars
Nektar Therapeutics stock hits 52-week high at 76.3 USD
Alerte résultats Nektar Therapeutics T4 2025 : hausse de trésorerie et expansion R&D
Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates
Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet
Nektar Therapeutics stock hits 52-week high at 75.19 USD
Nektar Therapeutics clôture une offre publique de 460 millions de dollars